Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 3/20 | 0.41 |
| ▸ | TK1 | P04183 | 2/20 | 0.40 |
| ▸ | TOP2A | P11388 | 3/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065019 | 0.92 | TK2 (0.42) | TK2TK1TOP2ATYMP | |
| SCHEMBL7065021 | 0.92 | TK2 (0.42) | TK2TK1TOP2ATYMP | |
| SCHEMBL261289 | 0.91 | TK2 (0.47) | TK2TK1TOP2ATYMP | |
| SCHEMBL261288 | 0.91 | TK2 (0.47) | TK2TK1TOP2ATYMP | |
| SCHEMBL19812217 | 0.91 | TK2 (0.47) | TK2TK1TOP2ATYMP | |
| SCHEMBL260669 | 0.91 | TK2 (0.41) | TK2TK1TOP2ATYMP | |
| SCHEMBL313035 | 0.91 | TK2 (0.41) | TK2TK1TOP2ATYMP | |
| SCHEMBL29254537 | 0.90 | TK2 (0.43) | TK2TK1TOP2ATYMP | |
| SCHEMBL29254539 | 0.90 | TK2 (0.43) | TK2TK1TOP2ATYMP | |
| SCHEMBL31723480 | 0.89 | TK2 (0.42) | TK2TK1TOP2ATYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6639062-B2 | Oligonucleotides which elicit ribonuclease for cleavage in complementary nucleic acid strand, having increased binding affinity/nuclease resistance; for medical diagnosis, gene therapy | ISIS PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | IONIS PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088079-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | HNRNPM, RNASEH1, HNRNPF | TK2 472/4885TK1 395/4885TOP2A 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.